In This Article
What MOTS-c Actually Is
MOTS-c stands for Mitochondrial Open Reading Frame of the Twelve S rRNA type-c. It's a 16-amino-acid peptide, but what makes it unusual is where it comes from - your mitochondrial DNA. Nearly every peptide discussed in health optimisation is encoded in your nuclear DNA (the main genome). MOTS-c comes from a completely different genome - the small, circular DNA inside your mitochondria.
This matters because mitochondria are your cellular energy factories. They produce ATP - the fuel that powers literally every process in your body. A peptide that comes from mitochondrial DNA and affects energy metabolism is, from a research perspective, extremely interesting.
MOTS-c was discovered in 2015 by Dr. Changhan David Lee's lab at USC. It's one of only a handful of known mitochondria-derived peptides, and it's the one with the strongest metabolic data.
What It Does In Your Body
- Activates AMPK - the master metabolic switch - AMPK is the enzyme that exercise activates. It's your body's energy sensor. When AMPK is on, your cells burn glucose for fuel, increase fat oxidation, improve insulin sensitivity, and resist metabolic stress. MOTS-c turns this switch on without exercise
- Improves insulin sensitivity - in animal models, MOTS-c improves how efficiently cells respond to insulin, which means better blood sugar control. This is the same benefit you get from regular exercise
- Increases fat burning - it shifts cellular metabolism toward fat oxidation, reducing reliance on glucose and promoting the use of stored fat for energy
- Surges during exercise - your body's MOTS-c levels increase approximately 12x in skeletal muscle during exercise, and circulating levels increase about 1.6x. This isn't a coincidence - it appears to be one of the key molecular signals that delivers exercise's metabolic benefits
- Reduces harmful inflammation - MOTS-c down-regulates inflammatory pathways that contribute to metabolic disease, obesity, and ageing
- Improves mitochondrial function - a 2025 study showed MOTS-c treatment restored mitochondrial respiration in type 2 diabetic heart tissue, improving the actual energy-producing capacity of damaged mitochondria
What The Research Shows
The Running Capacity Study
The headline finding from USC: old mice treated with MOTS-c doubled their running capacity on a treadmill test. They ran further and longer than untreated mice of the same age. The effect was particularly dramatic in aged mice, suggesting MOTS-c may specifically counteract age-related physical decline.
Metabolic Disease
In diet-induced obesity models, MOTS-c treatment delayed weight gain without reducing food intake - meaning the mice ate the same amount but gained less weight. This suggests MOTS-c directly increases metabolic rate. It also prevented insulin resistance in these models, even when mice were fed a high-fat diet.
Diabetic Heart Function (2025)
A study published in Frontiers in Physiology in 2025 showed that MOTS-c restored mitochondrial respiration in type 2 diabetic heart tissue. Diabetic hearts have impaired mitochondrial function - they can't produce energy efficiently. MOTS-c treatment improved this, suggesting potential applications for diabetic cardiovascular disease.
Age-Related Decline
MOTS-c levels naturally decline with age in both mice and humans. Studies show that physically active older adults have higher circulating MOTS-c levels than sedentary ones. This creates an interesting question: is the decline in MOTS-c a cause of age-related metabolic decline, or just a marker of it? The answer probably involves both.
The Critical Distinction: Exercise Mimetic ≠ Exercise Replacement
MOTS-c activates some of the same pathways as exercise, but exercise does hundreds of things simultaneously - cardiovascular adaptation, neuroplasticity, bone density maintenance, psychological benefits, microbiome changes. No single molecule replicates all of that. MOTS-c mimics the metabolic component. That's significant, but it's not the whole story.
The most realistic application isn't as an exercise replacement for healthy people - it's for people who can't exercise effectively due to age, disability, or metabolic disease. If your mitochondria are already compromised, a peptide that restores their function has a much stronger rationale than using it to skip the gym.
Who Uses It
- Longevity clinicians - as part of metabolic optimisation protocols, particularly for patients with early insulin resistance or metabolic syndrome
- Patients who can't exercise - due to injury, disability, or post-surgical recovery. The logic: maintain metabolic health when physical activity isn't possible
- Biohackers and athletes - for potential metabolic enhancement, though the evidence for added benefit on top of regular exercise is minimal
Dosing - What The Community Uses
- 5-10mg subcutaneously, typically 3-5 times per week
- Some protocols use daily dosing at 5mg
- Cycle length: 4-8 weeks, often cycled with other metabolic peptides
These are community-derived protocols. No human clinical trial has established optimal dosing for MOTS-c.
The Honest Bottom Line
MOTS-c is one of the most scientifically interesting peptides in current research. It comes from mitochondrial DNA (unusual), it mimics exercise at the molecular level (significant), and the animal data is compelling - doubled running capacity, prevented obesity without reducing food intake, restored diabetic mitochondrial function. But it's still early-stage. There are no large human clinical trials. The gap between "works impressively in mice" and "proven to work in humans" is where most promising drugs go to die. Watch this space, but calibrate your expectations accordingly.
For the full peptide landscape, read the Complete Peptide Guide.
This article is for educational purposes only. It is not medical advice. Peptides discussed here may not be approved for human use in your country. Always consult a qualified medical professional before making any health decisions.